---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095537"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:07:41.948846+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dyne Q2 net loss $65.1M, cash $778.8M; ACHIEVE/DELIVER data positive

## Summary
- Q2 2024 net loss $65.1M ($0.70/sh) vs $64.9M ($1.08/sh) in Q2 2023.
- Cash, cash equivalents and marketable securities $778.8M, funded at least into H2 2026.
- Completed $374.3M public offering (12.075M shares at $31.00) in May 2024.
- DYNE-101 in DM1 showed splicing correction and functional improvement; DYNE-251 in DMD showed dystrophin expression exceeding eteplirsen at 6 months.
- Company plans to provide registration path update for both programs by year-end 2024.

## SEC filing metadata
- accession: 0000950170-24-095537
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017024095537/0000950170-24-095537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017024095537/dyn-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095537
- JSON: https://secwatch.observer/filing/0000950170-24-095537.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.